Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

AGIO stock hub

Agios Pharmaceuticals, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

AGIOis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.7B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

AGIO

In the news

Latest news · AGIO

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-32.8

P25 -105.6P50 -46.5P75 -3.1

ROIC-120.9

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All AGIO market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

204

Groups with data

Currency

USD

Showing 204 of 204 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001439222
Company name	Agios Pharmaceuticals, Inc.
Country	United States
Country code	US
Cusip	00847X104
Employees	540
Employees Change	52%
Employees Change Percent	10.66
Enterprise value	$643M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2013-07-24
Isin	US00847X1046
Last refreshed	2026-05-10
Market cap	$1.7B
Market cap category	Small-Cap
Price	$27.79
Price currency	USD
Rev Per Employee	122,311.11x
Sector	Healthcare
Sic	2834
Symbol	AGIO
Website	https://www.agios.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-25.57%
EV Sales Forward	6.77x
EV/Sales	9.73x
FCF yield	-23.28%
P/B ratio	1.49x
P/S ratio	25.02x
PS Forward	17.4x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-288.5M
Net Income	$-422.6M
Net Income Growth Years	0%
Pretax Margin	-641.38%
Profit Per Employee	$-782,598
ROA	-21.69
Roa5y	-20.34
ROCE	-42.23
ROE	-32.82
Roe5y	-14.25
ROIC	-120.9
Roic5y	-138.4

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-4.4%
Cagr1y	-1.52%
Cagr3y	2.85%
Cagr5y	-13.01%
EPS Growth Years	0
Revenue Growth	78.34x
Revenue Growth Q	137.75x
Revenue Growth Quarters	13x
Revenue Growth Years	3x
Revenue Growth3 Y	51.44x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.05
Assets	$1.2B
Cash	$737M
Current Assets	$834.8M
Current Liabilities	$58.8M
Debt	$35.7M
Debt Equity	$0.03
Equity	$1.1B
Liabilities	$75.9M
Long Term Assets	$350.1M
Long Term Liabilities	$17M
Net Cash	$1B
Net Cash By Market Cap	$61.1
Net Cash Growth	-26.39%
Net Debt Equity	$-0.91
Tangible Book Value	$1.1B
Tangible Book Value Per Share	$18.69
WACC	7.26

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	14.19
Inventory Turnover	10.96
Net Working Capital	$57.8M
Quick ratio	12.8
Working Capital	$776M
Working Capital Turnover	$0.08

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.25%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-36.23%
1Y total return	-1.52%
200-day SMA	32.9
3Y total return	8.81%
50-day SMA	29.47
50-day SMA vs 200-day SMA	50under200
5Y total return	-50.19%
All Time High	138.9
All Time High Change	-79.99%
All Time High Date	2015-01-15
All Time Low	15.77
All Time Low Change	76.22%
All Time Low Date	2013-11-18
ATR	1.43
Beta	0.58
Beta1y	2.14
Beta2y	1.9
Ch YTD	2.09
High	28.21
High52	46
High52 Date	2025-11-18
High52ch	-39.59%
Low	27.5
Low52	22.24
Low52 Date	2025-11-19
Low52ch	24.96%
Ma50ch	-5.71%
Premarket Change Percent	1.09
Premarket Price	$27.83
Premarket Volume	479
Price vs 200-day SMA	-15.53%
RSI	45.92
RSI Monthly	44.49
RSI Weekly	45.92
Sharpe ratio	0.4x
Sortino ratio	0.54
Total Return	-0.25%
Tr YTD	2.09
Tr1m	-20.85%
Tr1w	-1.31%
Tr3m	4.75%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	8
Analyst Count Top	2
Analyst Price Target Top	$38.5
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-1.79
Earnings Revenue Estimate	13,830,712x
Earnings Revenue Estimate Growth	58.5x
Operating Income	$-475.5M
Operating margin	-720
Price target	$38.63
Price Target Change	$39.01
Price Target Change Top	$38.54

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	50,618,619%
Float Percent	85.11%
Shares Insiders	1.11%
Shares Institutions	94.43%
Shares Out	59,471,609
Shares Qo Q	0.74%
Shares Yo Y	0.25%
Short Float	13.99%
Short Ratio	6.79
Short Shares	11.91

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-441.5M
Average Volume	1,325,594.5x
Bv Per Share	18.69
CAPEX	$-4.3M
Ch10y	-36.23
Ch1m	-20.85
Ch1w	-1.31
Ch1y	-1.52
Ch3m	4.75
Ch3y	8.81
Ch5y	-50.19
Ch6m	-31.67
Change	0.94%
Change From Open	1.05
Close	27.53
Days Gap	-0.11
Depreciation Amortization	5,262,000
Dollar Volume	16,199,819.2
Earnings Date	2026-04-29
Earnings Time	bmo
EBIT	$-475.5M
EBITDA	$-470.3M
EPS	$-7.25
F Score	3
FCF	$-384.7M
FCF EV Yield	-59.84x
FCF Per Share	$-6.47
Financing CF	9,135,000
Fiscal Year End	December
Founded	2,007
Income Tax	$-1M
Investing CF	405,909,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-04-29
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-12
Ma150	31.38
Ma150ch	-11.43%
Ma20	28.63
Ma20ch	-2.93%
Net CF	34,636,000
Next Earnings Date	2026-07-30
Open	27.5
Optionable	Yes
Position In Range	40.85
Ppne	37,762,000
Pre Close	27.53
Price Date	2026-05-08
Ptbv Ratio	1.49
Relative Volume	0.44x
Revenue	66,048,000x
SBC By Revenue	85.9x
Share Based Comp	56,734,000
Tax By Revenue	-1.54x
Tr6m	-31.67%
Us State	Massachusetts
Volume	582,937
Z Score	13.86

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does AGIO pay a dividend?

Capital-return profile for this ticker.

Performance

AGIO stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns AGIO?

Insider, institutional, and short-interest positioning.

Institutional ownership

+94.4%

Float: +85.1% of shares outstanding

Insider ownership

+1.1%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

AGIO momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

45.9

Neutral momentum band

Price vs 200-day MA

-15.5%

50/200-day relationship not available

Beta (5Y)

0.58

Less volatile than the market

Sharpe ratio

0.40

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About AGIO

Hub-level FAQ points readers to the deeper analysis pages.

What is the current AGIO stock rating?

Agios Pharmaceuticals, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full AGIO analysis?

The full report lives at /stocks/AGIO/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for AGIO?

The latest report frames AGIO around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the AGIO page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.